Previous 10 | Next 10 |
NEW YORK, Oct. 14, 2020 (GLOBE NEWSWIRE) -- Seed Therapeutics Inc. (the “Company” or “Seed Therapeutics”), a global research company and BeyondSpring subsidiary focused on harnessing and engineering “molecular glue,” a targeted protein degradation (...
NEW YORK, Oct. 12, 2020 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative immuno-oncology and chemotherapy-induced neutropenia therapies, announc...
JAMA Oncology, the American Medical Association’s peer-reviewedjournal published BeyondSpring's ([[BYSI]] -0.3%) manuscript, titled 'Efficacy of Plinabulin vs. Pegfilgrastim for Prevention of Chemotherapy-Induced Neutropenia in Adults With Non-Small Cell ...
NEW YORK, Sept. 29, 2020 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on developing innovative immuno-oncology therapies to transform the lives of patients with unmet me...
Akero Therapeutics to continue with mid stage Efruxifermin trial. BioMarin initiated mid stage study for BMN 307. BeyondSpring presents positive data for Plinabulin in preventing neutropenia. For further details see: Akero Continues Efruxifermin Trial, And Other News: Th...
BeyondSpring ([[BYSI]] -0.6%) has announced new data on its lead drug plinabulin, demonstrating it to be a favorable option for preventing chemo-induced neutropenia ((CIN)) during the pandemic, compared to Amgen's Neulasta (pegfilgrastim, Peg), long-lasting G-CSF.In terms of severe ...
NEW YORK, Sept. 24, 2020 (GLOBE NEWSWIRE) -- BeyondSpring Inc . (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on developing innovative immuno-oncology therapies to transform the lives of patients with unmet m...
BeyondSpring (BYSI) has appointed Elizabeth Czerepak as Chief Financial Officer, effective immediately. The company's subsidiary, Seed Therapeutics has appointed Edward Liu as Chief Financial Officer. Mr. Liu will also retain his responsibilities as CFO of BeyondSpring, China. Ms. Czerep...
NEW YORK, Sept. 22, 2020 (GLOBE NEWSWIRE) -- Following its recent receipt of two Breakthrough Therapy Designations in both the U.S. and China for Plinabulin in the chemotherapy-induced neutropenia (CIN) indication, BeyondSpring Inc. (the “Company” or “BeyondSpri...
NEW YORK, Sept. 11, 2020 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on developing innovative immuno-oncology cancer therapies to transform the lives of patients with unmet med...
News, Short Squeeze, Breakout and More Instantly...
COPT Defense Properties of Beneficial Interest (CDP) is expected to report $0.64 for Q2 2024 Bank of Marin Bancorp (BMRC) is expected to report $0.19 for Q2 2024 Oak Ridge Financial Services Inc (BKOR) is expected to report for Q2 2024 D/B/A Centerspace (CSR) is expected to report $1....
A look at the top 10 most actives in the United States Greenwave Technology Solutions Inc. (GWAV) rose 12.4% to $0.0886 on volume of 1,366,648,994 shares Ascent Solar Technologies Inc (ASTI) rose 63.4% to $0.2147 on volume of 656,794,712 shares Pineapple Energy Inc. (PEGY) rose 61.4% to $...
FLORHAM PARK, N.J., May 16, 2024 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI) (“BeyondSpring” or the “Company”), a clinical-stage global biopharmaceutical company focused on developing innovative cancer therapies, today announced that it hosted a virtua...